Top Markets
Coin of the day
Nanobiotix S.A. Nanobiotix S.A.

Nanobiotix S.A.

NANO
Rang in aandelen #5949
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on... Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Aandeelprijs
$45.79
Marktkapitalisatie
$2.33B
Verandering (1 dag)
11.43%
Verandering (1 jaar)
408.10%
Land
FR
Handel Nanobiotix S.A. (NANO)

Categorie

Dividendrendementgeschiedenis voor Nanobiotix S.A. (NANO)
Het dividendrendement (TTM) van Nanobiotix S.A. (aandelsymbool: NANO) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Nanobiotix S.A. (NANO) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH